On Thursday to Friday, November 30 to December 1, 2017, the Blood Products Advisory Committee (BPAC) discussed and voted on the following topics:

·         Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion;

·         Device classification of human leukocyte antigen, human platelet antigen, and human neutrophil antigen devices; and

·         Strategies to reduce the risk of transfusion-transmitted Zika virus.

The Committee also heard information about the April 6, 2017 FDA public workshop on emerging tick-borne diseases and blood safety, as well as the Transfusion Transmissible Infections Monitoring System.